Physician profile
Raymond E Sisk
NPI 1699067645
$1,652.71
in general payments reported to CMS, 2019-2025
22 companies · $29.68 in 2025
The $29.68 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,099 · 2022: $459 · 2023: $64.58 · 2025: $29.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $419.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $259.97 | 2021 | |
| Mylan Specialty L.P. | $228.00 | 2021-2023 | Yupelri |
| Grifols USA, LLC | $78.46 | 2021-2022 | |
| Genzyme Corporation | $74.44 | 2021 | |
| Abbvie INC. | $70.85 | 2022 | |
| Merck Sharp & Dohme LLC | $60.90 | 2021-2022 | |
| Electromed, INC. | $59.96 | 2021-2022 | |
| Novo Nordisk INC | $58.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.83 | 2022 | |
| Daiichi Sankyo INC. | $35.77 | 2021 | |
| Advanced Respiratory, INC | $33.69 | 2021 | |
| Eisai INC. | $31.94 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $29.68 | 2025 | |
| Lilly USA, LLC | $28.11 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.77 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $25.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.31 | 2021 | |
| Amgen INC. | $16.30 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.77 | 2021 | |
| Sumitomo Pharma America, INC. | $15.42 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Sisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.